Top

Forensic Toxicology

Published in:

Open Access 01-07-2018 | Original Article

In vitro metabolism of synthetic cannabinoid AM1220 by human liver microsomes and Cunninghamella elegans using liquid chromatography coupled with high resolution mass spectrometry

Authors: Shimpei Watanabe, Unnikrishnan Kuzhiumparambil, Shanlin Fu

Published in: Forensic Toxicology | Issue 2/2018

Abstract

Purpose

Identifying intake of synthetic cannabinoids generally requires the metabolism data of the drugs so that appropriate metabolite markers can be targeted in urine testing. However, the continuous appearance of new cannabinoids during the last decade has made it difficult to keep up with all the compounds including {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone (AM1220). In this study, metabolism of AM1220 was investigated with human liver microsomes and the fungus Cunninghamella elegans.

Methods

Metabolic stability of AM1220 was analysed by liquid chromatography–tandem mass spectrometry in multiple reaction monitoring mode after 1 µM incubation in human liver microsomes for 30 min. Tentative structure elucidation of metabolites was performed on both human liver microsome and fungal incubation samples using liquid chromatography–high-resolution mass spectrometry.

Results

Half-life of AM1220 was estimated to be 3.7 min, indicating a high clearance drug. Nine metabolites were detected after incubating human liver microsomes while seven were found after incubating Cunninghamella elegans, leading to 11 metabolites in total (five metabolites were common to both systems). Demethylation, dihydrodiol formation, combination of the two, hydroxylation and dihydroxylation were the observed biotransformations.

Conclusions

Three most abundant metabolites in both human liver microsomes and Cunninghamella elegans were desmethyl, dihydrodiol and hydroxy metabolites, despite different isomers of dihydrodiol and hydroxy metabolites in each model. These abundant metabolites can potentially be useful markers in urinalysis for AM1220 intake.

D’Ambra TE, Eissenstat MA, Abt J, Ackerman JH, Bacon ER, Bell MR, Carabateas PM, Josef KA, Kumar V, Weaver Iii JD, Arnold R, Casiano FM, Chippari SM, Haycock DA, Kuster JE, Luttinger DA, Stevenson JI, Ward SJ, Hill WA, Khanolkar A, Makriyannis A (1996) C-Attached aminoalkylindoles: potent cannabinoid mimetics. Bioorg Med Chem Lett 6:17–22. https://doi.org/10.1016/0960-894X(95)00560-G CrossRef

Makriyannis A, Deng H (2008) Cannabimimetic indole derivatives. US 2008/0090871 A1

Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125. https://doi.org/10.1007/s11419-012-0136-7 CrossRef

Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter V (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. Forensic Toxicol 30:126–134. https://doi.org/10.1007/s11419-012-0137-6 CrossRef

Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Uemura N, Hamano T (2013) Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area. Forensic Toxicol 31:76–85. https://doi.org/10.1007/s11419-012-0169-y CrossRef

Salomone A, Luciano C, Di Corcia D, Gerace E, Vincenti M (2014) Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers. Drug Test Anal 6:126–134. https://doi.org/10.1002/dta.1556 CrossRefPubMed

Langer N, Lindigkeit R, Schiebel H-M, Ernst L, Beuerle T (2014) Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test Anal 6:59–71. https://doi.org/10.1002/dta.1499 CrossRefPubMed

Blakey K, Boyd S, Atkinson S, Wolf J, Slottje PM, Goodchild K, McGowan J (2016) Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense. Forensic Sci Int 260:40–53. https://doi.org/10.1016/j.forsciint.2015.12.001 CrossRefPubMed

Nakajima J, Takahashi M, Uemura N, Seto T, Fukaya H, Suzuki J, Yoshida M, Kusano M, Nakayama H, Zaitsu K, Ishii A, Moriyasu T, Nakae D (2015) Identification of N, N-bis(1-pentylindol-3-yl-carboxy)naphthylamine (BiPICANA) found in an herbal blend product in the Tokyo metropolitan area and its cannabimimetic effects evaluated by in vitro [³⁵S]GTPγS binding assays. Forensic Toxicol 33:84–92. https://doi.org/10.1007/s11419-014-0253-6 CrossRef

10.

Zaitsu K, Nakayama H, Yamanaka M, Hisatsune K, Taki K, Asano T, Kamata T, Katagai M, Hayashi Y, Kusano M, Tsuchihashi H, Ishii A (2015) High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. Int J Legal Med 129:1233–1245. https://doi.org/10.1007/s00414-015-1257-4 CrossRefPubMed

11.

Diao X, Huestis MA (2017) Approaches, challenges, and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin Pharmacol Ther 101:239–253. https://doi.org/10.1002/cpt.534 CrossRefPubMed

12.

Kim U, Jin MJ, Lee J, Han SB, In MK, Yoo HH (2012) Tentative identification of phase I metabolites of HU-210, a classical synthetic cannabinoid, by LC-MS/MS. J Pharm Biomed Anal 64-65:26–34. https://doi.org/10.1016/j.jpba.2012.02.007 CrossRefPubMed

13.

Kim JH, Kim HS, Kong TY, Lee JY, Kim JY, In MK, Lee HS (2016) In vitro metabolism of a novel synthetic cannabinoid, EAM-2201, in human liver microsomes and human recombinant cytochrome P450s. J Pharm Biomed Anal 119:50–58. https://doi.org/10.1016/j.jpba.2015.11.023 CrossRefPubMed

14.

Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA (2015) Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J 17:660–677. https://doi.org/10.1208/s12248-015-9721-0 CrossRefPubMedPubMedCentral

15.

Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA (2016) In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J 18:455–464. https://doi.org/10.1208/s12248-016-9867-4 CrossRefPubMedPubMedCentral

16.

Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA (2017) In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol 35:20–32. https://doi.org/10.1007/s11419-016-0326-9 CrossRefPubMed

17.

Jang M, Yang W, Shin I, Choi H, Chang H, Kim E (2014) Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse. Int J Legal Med 128:285–294. https://doi.org/10.1007/s00414-013-0884-x CrossRefPubMed

18.

Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V (2011) Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B 879:2519–2526. https://doi.org/10.1016/j.jchromb.2011.07.004 CrossRef

19.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF (2017) In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicol 35:333–347. https://doi.org/10.1007/s11419-017-0361-1 CrossRefPubMedPubMedCentral

20.

Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S (2016) Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans. Forensic Sci Int 261:33–42. https://doi.org/10.1016/j.forsciint.2015.12.023 CrossRefPubMed

21.

Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S (2016) Data on individual metabolites of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans. Data Brief 7:332–340. https://doi.org/10.1016/j.dib.2016.02.039 CrossRefPubMedPubMedCentral

22.

Watanabe S, Kuzhiumparambil U, Nguyen MA, Cameron J, Fu S (2017) Metabolic profile of synthetic cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans. AAPS J 19:1148–1162. https://doi.org/10.1208/s12248-017-0078-4 CrossRefPubMed

23.

Steuer AE, Williner E, Staeheli S, Kraemer T (2017) Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal 9:1085–1092. https://doi.org/10.1002/dta.2111 CrossRefPubMed

24.

Pasin D, Cawley A, Bidny S, Fu S (2017) Current applications of high-resolution mass spectrometry for the analysis of new psychoactive substances: a critical review. Anal Bioanal Chem 409:5821–5836. https://doi.org/10.1007/s00216-017-0441-4 CrossRefPubMed

25.

Nunomoto S, Kawakami Y, Yamashita Y, Takeuchi H, Eguchi S (1990) Regioselectivity control in alkylation reactions of indolyl ambident anion. J Chem Soc Perkin Trans 1 1990:111–114. https://doi.org/10.1039/P19900000111 CrossRef

26.

Okauchi T, Itonaga M, Minami T, Owa T, Kitoh K, Yoshino H (2000) A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminum chloride. Org Lett 2:1485–1487. https://doi.org/10.1021/ol005841p CrossRefPubMed

27.

Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–1359 (PMID: 10534321) PubMed

28.

Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–1324 (PMID: 11560875) PubMed

29.

Choudhary MI, Khan NT, Musharraf SG, Anjum S, Atta-ur-Rahman (2007) Biotransformation of adrenosterone by filamentous fungus, Cunninghamella elegans. Steroids 72:923–929. https://doi.org/10.1016/j.steroids.2007.08.002 CrossRefPubMed

30.

McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, Sanders M (2008) An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev Technol 6:121–129. https://doi.org/10.1089/adt.2007.103 CrossRefPubMed

31.

Lavé T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152–155. https://doi.org/10.1023/a:1012036324237 CrossRefPubMed

32.

Wood JT, Smith DM, Janero DR, Zvonok AM, Makriyannis A (2013) Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci 92:482–491. https://doi.org/10.1016/j.lfs.2012.06.019 CrossRefPubMed

33.

Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR (2016) Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal 8:1039–1048. https://doi.org/10.1002/dta.1938 CrossRefPubMed

34.

Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4:745–753. https://doi.org/10.1002/dta.1418 CrossRefPubMed

35.

Wang R-F, Cao W-W, Khan AA, Cerniglia CE (2000) Cloning, sequencing, and expression in Escherichia coli of a cytochrome P450 gene from Cunninghamella elegans. FEMS Microbiol Lett 188:55–61. https://doi.org/10.1111/j.1574-6968.2000.tb09168.x CrossRefPubMed

36.

Asha S, Vidyavathi M (2009) Cunninghamella–a microbial model for drug metabolism studies—a review. Biotechnol Adv 27:16–29. https://doi.org/10.1016/j.biotechadv.2008.07.005 CrossRefPubMed

37.

Zhang D, Yang Y, Leakey JEA, Cerniglia CE (1996) Phase I and phase II enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics. FEMS Microbiol Lett 138:221–226. https://doi.org/10.1111/j.1574-6968.1996.tb08161.x CrossRefPubMed

38.

Dube AK, Kumar MS (2017) Biotransformation of bromhexine by Cunninghamella elegans, C. echinulata and C. blakesleeana. Braz J Microbiol 48:259–267. https://doi.org/10.1016/j.bjm.2016.11.003 CrossRefPubMed

39.

Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174–2184. https://doi.org/10.1124/dmd.112.047530 CrossRefPubMedPubMedCentral

40.

Kaminsky LS, Zhang Z-Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74. https://doi.org/10.1016/S0163-7258(96)00140-4 CrossRefPubMed

41.

Wong YWJ, Davis PJ (1989) Microbial models of mammalian metabolism: stereoselective metabolism of warfarin in the fungus Cunninghamella elegans. Pharm Res 6:982–987. https://doi.org/10.1023/A:1015905832184 CrossRefPubMed

42.

Olesen OV, Linnet K (1997) Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 55:235–243. https://doi.org/10.1159/000139533 CrossRefPubMed

43.

Zhang D, Evans FE, Freeman JP, Duhart B Jr, Cerniglia CE (1995) Biotransformation of amitriptyline by Cunninghamella elegans. Drug Metab Dispos 23:1417–1425 (PMID: 8689954) PubMed

Title: In vitro metabolism of synthetic cannabinoid AM1220 by human liver microsomes and Cunninghamella elegans using liquid chromatography coupled with high resolution mass spectrometry
Authors: Shimpei Watanabe
Unnikrishnan Kuzhiumparambil
Shanlin Fu
Publication date: 01-07-2018
Publisher: Springer Japan
Published in: Forensic Toxicology / Issue 2/2018
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-018-0424-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

In vitro metabolism of synthetic cannabinoid AM1220 by human liver microsomes and Cunninghamella elegans using liquid chromatography coupled with high resolution mass spectrometry

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

The internal standard diquat-d4 causes errors in diquat analysis by LC–MS/MS

Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds

Effects of the new generation α-pyrrolidinophenones on spontaneous locomotor activities in mice, and on extracellular dopamine and serotonin levels in the mouse striatum

MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB1- and CB2-receptor-dependent manner in conscious rats

Long-term stability of synthetic cathinones in dried blood spots and whole blood samples: a comparative study

Pentobarbital use in a decomposed suicide